2013 Pathology Student

Size: px
Start display at page:

Download "2013 Pathology Student"

Transcription

1 About this guide If you re reading this introduction, it means you are probably either a) covering hematopathology in your pathology class right now, or b) studying for boards. Either way, you ve come to the right study guide! Inside, you ll find a comprehensive (but not oppressive) review of both benign and malignant hematopathology, neatly summarized and nicely illustrated. Whether you have a read-the-text-straight-through kind of mind, or a looking-at-pictures mind, or a question-working mind, you ll find it easy to work your way through this guide. Extra help If you are stuck, or frustrated, or if something just doesn t make sense, feel free to me at pathology@pathologystudent.com. I ll do my best to get you unstuck and back on track Pathology Student

2 Table of Contents 1. Introduction p Anemia p Benign leukocytoses.. p Leukemia p. 46 Acute myeloid leukemia.. p. 48 Myelodysplastic syndromes p. 59 Acute lymphoblastic leukemia p. 60 Chronic myeloproliferative disorders.. p. 65 Chronic lymphoproliferative disorders p Myeloma.. p Lymph node disorders. p. 80 Benign lymph node disorders. p. 80 Non-Hodgkin lymphoma. p. 83 Hodgkin disease.. p Reference section. p Study questions. p. 102 page 2

3 List of Diseases Anemia Iron-deficiency anemia Megaloblastic anemia Hemolytic anemias Hereditary spherocytosis G6PD deficiency Sickle cell anemia Thalassemia Warm autoimmune hemolytic anemia Cold autoimmune hemolytic anemia Microangiopathic hemolytic anemia Anemia of chronic disease Anemia of chronic renal disease Anemia of chronic liver disease Aplastic anemia Benign leukocytoses Benign neutrophilia Benign lymphocytosis Other leukocytoses Leukemia Acute myeloid leukemia AML with genetic abnormalities AML with FLT3 mutation AML with multilineage dysplasia AML, therapy-related AML, not otherwise classified Myelodysplastic syndromes Acute lymphoblastic leukemia T-cell ALL B-cell precursor ALL Burkitt leukemia Chronic myeloproliferative disorders Chronic myeloid leukemia Chronic myelofibrosis Polycythemia vera Essential thrombocythemia Chronic lymphoproliferative disorders Chronic lymphocytic leukemia Hairy cell leukemia Prolymphocytic leukemia Large granular lymphocyte leukemia Myeloma Lymph node disorders Benign lymph node disorders Non-Hodgkin lymphoma Small lymphocytic lymphoma Marginal zone lymphoma Mantle cell lymphoma Follicular lymphoma Mycosis fungoides/sézary syndrome Diffuse large B-cell lymphoma Lymphoblastic lymphoma Burkitt lymphoma Adult T-cell leukemia/lymphoma Hodgkin disease Nodular lymphocyte predominance Nodular sclerosis Mixed cellularity Lymphocyte rich Lymphocyte depletion

4 Chronic Leukemias Chronic leukemias are very different from acute leukemias. Chronic leukemias are for the most part diseases of older adults (acute leukemias occur in both children and adults). They appear in an insidious fashion and have a relatively good prognosis (as opposed to acute leukemias, which have a stormy onset and poor prognosis). In addition, chronic leukemias are composed of fairly mature-appearing hematopoietic cells (as opposed to acute leukemias, which are composed of blasts). There are two kinds of chronic leukemias: myeloid and lymphoid. Instead of being reasonable, and calling them chronic myeloid leukemias and chronic lymphoid leukemias, the powers that be dubbed the two divisions chronic myeloproliferative disorders and chronic lymphoproliferative disorders. These names are not so great, in my opinion, since these are not just disorders they are real leukemias! But no one asked me. Pathophysiology The chronic leukemias are malignant, monoclonal proliferations of mostly mature myeloid or lymphoid cells in the bone marrow (and blood). These leukemias progress more slowly than acute leukemias. So early on, the marrow is involved but not totally replaced by malignant cells. Still, it is hard for the normal white cells to function properly. The lymphoid cells, in particular, have a hard time making normal immunoglobulin in certain chronic lymphoproliferative disorders. One of the major causes of mortality in these patients is infection. As the chronic leukemias evolve, more and more of the marrow is replaced by tumor, and eventually there is little room for normal white cells to grow. Clinical Features Chronic leukemias present in over a period of weeks or months. Patients might have splenomegaly (which shows up as a dragging sensation or fullness in the left upper quadrant of the abdomen), lymphadenopathy, or a general feeling of malaise and fatigue. Some patients are asymptomatic at diagnosis, and the disease is picked up on a routine blood smear or CBC. Likewise, the clinical course is different in chronic leukemia. In many cases of chronic leukemia, patients can live for years without treatment at all. page 4

5 Chronic Myeloproliferative Disorders The chronic myeloproliferative disorders are malignant clonal proliferations of a pluripotent stem cell that lead to excessive proliferation of myeloid cells in the blood and bone marrow. What that means in plain English is that a stem cell somewhere way back (before it s even committed to the neutrophil line, or red cell line) goes bad and starts proliferating like crazy so you wind up with a marrow packed with cells from all the myeloid lineages (the official name is panhyperplasia ). Usually, one particular myeloid lineage predominates in this growth fest so you ll see a ton of all the myeloid cells, but the majority are neutrophils, or red cells, or megakaryocytes. So the chronic myeloproliferative disorders have been divided into four types according to what is proliferating most: Chronic myeloid leukemia (tons of neutrophils and precursors) Polycythemia vera (tons of red cells and precursors) Essential thrombocythemia (tons of platelets and megakaryocytes) Chronic myelofibrosis (tons of everything then nothing! See below.) Chronic myeloproliferative disorders: CML, PV, ET, and chronic myelofibrosis We ll consider each of these separately because they are very different clinically and morphologically. But they do have some common features: all of them have a high white count with a left shift, a hypercellular marrow, and splenomegaly. Chronic myeloid leukemia Chronic myeloid leukemia (CML) is a chronic myeloproliferative disorder characterized by a marked proliferation of neutrophils (and precursors) in the bone marrow and blood. All cases have a t(9;22), also known as the Philadelphia chromosome (it s the 22 that s officially the Philadelphia chromosome). Clinical Features CML frequently occurs in patients who are around 40 or 50. It does not occur in children (though there is a separate disease similar to CML, called juvenile CML, that does occur in kids). Usually, the onset is slow, with a long asymptomatic period, followed by fevers, fatigue, night sweats and abdominal fullness. On physical exam, patients usually have an enlarged spleen. Hepatomegaly and lymphadenopathy may also be present. CML has a t(9;22). page 5

6 There are three clinical stages, or phases, of CML: chronic phase, accelerated phase and blast crisis. Patients generally present in chronic phase and then progress to one or both of the other phases. Chronic phase High but stable number of neutrophils and precursors. Stable hemoglobin and platelet count. Easily controlled by therapy. With traditional treatment (not imatinib, see below), usually lasts 3-4 years; is then followed by accelerated phase and/or blast crisis. Accelerated phase Characterized by a change in the patient's previously stable state. Usually see increasing leukocytosis, decreasing hemoglobin and platelet count. May terminate in this stage, or may progress to blast crisis. Usually fatal within several months. Chronic myeloid leukemia: marked neutrophilia, left shift, and basophilia Blast crisis Characterized by a marked increase in blasts (myeloblasts or lymphoblasts). Usually fatal within a few weeks or months. Morphology Blood The blood smear shows a marked neutrophilia with a left shift. The left shift is a little weird in that it is not evenly distributed between all the neutrophil stages. There are tons of neutrophils at all stages of development, but there are relatively more myelocytes and segmented neutrophils (and relatively less of the other stages). There are a few myeloblasts around (which you don t see in normal blood, of course) but they don t number more than 2 or 3%. Here s an interesting thing: patients with CML almost always have a basophilia. That s actually one of the first things that happens in the development of the disease! There are few if any other reasons for a basophilia. So if you see this in a patient, even if they don t have the typical findings of CML (big white count with lots of neutrophils and precursors), you should rule out CML! The platelet count may be increased (because of all the megakaryocytes around in the bone marrow). CML: blood page 6

7 Bone marrow The bone marrow is hypercellular, with a pan-myeloid hyperplasia (all the myeloid cells are increased neutrophils and precursors, red cell precursors, megakaryocytes). However, if you look closely, you ll see that the neutrophils and precursors make up the bulk of the cells. Later in the course of the disease, the marrow may become fibrotic. You can detect this using a reticulin stain. This is not a good sign. Pathophysiology All cases of CML have a translocation between chromosomes 9 and 22, resulting in what s commonly known as the Philadelphia chromosome (Ph). This designation refers to the new chromosome 22 that results from the translocation. Nobody talks about poor chromosome 9. The translocation places the c-abl proto-oncogene on chromosome 9 next to the bcr gene on chromosome 22. A new, fusion gene is created: the bcr-abl gene. The bcr-abl gene encodes a protein called p210, which increases tyrosine kinase activity and disrupts the cell cycle. Here s a weird fact: the Philadelphia chromosome is found not only in the myeloid cells, but also in some B lymphocytes! That s weird, considering that this is a myeloid lesion with no apparent changes in the lymphoid cells. This probably means that the initial bad cell (the one that became malignant) was a very early stem cell, one that hadn t even committed itself to myeloid or lymphoid lineage yet, and the Philadelphia chromosome is present in all the descendents of that cell. Further supporting this idea is the fact that when patients enter blast crisis, the blasts can be lymphoid! CML: bone marrow Treatment and Prognosis In the old days, CML was treated with myelosuppressive agents like hydroxyurea, and then if the patient had a match and could tolerate it, allogeneic bone marrow transplant was performed. That was the only hope for a cure. Recently, a new drug called imatinib (or Gleevec) was developed that targets the messed-up tyrosine kinase receptor activity in CML. It has been like a miracle for many patients even patients in the later stages of the disease. In fact, we don t even know what the typical prognosis of CML is anymore, because these patients are still living with the disease. This drug has turned CML into a chronic but treatable disease, like diabetes, for many patients. It s one of the happiest leukemia research stories ever. page 7

8 Chronic myelofibrosis Chronic myelofibrosis, also called idiopathic myelofibrosis or agnogenic myeloid metaplasia, is a chronic myeloproliferative disorder characterized by panmyelosis, bone marrow fibrosis, and extramedullary hematopoiesis. In real words: the bone marrow at first is markedly hypercellular, but over time, it becomes fibrotic, and the hematopoietic cells go elsewhere (most often, to the spleen) to try to make a home. Clinical Features Like the other chronic leukemias, chronic myelofibrosis is a disease of older adults. The peak age is in the late 50s. The disease presents over a relatively long period of time, with symptoms of splenomegaly (left upper quadrant pain and fullness, epigastric pressure) and anemia (weakness, fatigue, and palpitations). A small number of patients are asymptomatic at diagnosis. Physical examination shows massive splenomegaly in most patients, as well as signs of anemia (pallor, tachycardia). Morphology Blood The blood smear shows a leukoerythroblastosis (remember this term from benign leukocytoses? If not, see page 41). There are lots of teardrop red cells in the blood due to the tight spaces (fibrotic marrow, big spleen) the red cells have to squeeze through. The platelets are often weird looking (large and hypogranular). Bone marrow Early on, the marrow is hypercellular, with a pan-myeloid hyperplasia. Megakaryocytes, in particular, are markedly increased in number. Later on, the marrow becomes fibrotic, and in the end stages of the disease, it is entirely replaced by fibrotic tissue, with very few remaining hematopoietic cells. Pathophysiology The cause of the fibrosis is still not completely worked out. The fibroblasts are benign so why are they so active? It s probably a result of megakaryocyte stimulation. Megakaryocytes are known to release cytokines that stimulate fibrosis and in chronic myelofibrosis, there are tons of megakaryocytes around. So this seems like a plausible explanation. Chronic myelofibrosis: blood Chronic myelofibrosis: marrow fibrosis, extramedullary hematopoiesis and teardrop red cells Chronic myelofibrosis: bone marrow page 8

9 Treatment and Prognosis Chronic myelofibrosis has a relatively long course (mean survival is 5 years). Treatment usually consists of supportive measures (like red cell transfusions) and myelosuppressive therapy (like hydroxyurea) if the patient can tolerate it. The cause of death in patients with chronic myelofibrosis is usually marrow failure. A small number of patients undergo leukemic transformation (meaning that they develop an acute leukemia like the blast crisis phase we talked about in CML). Interestingly, the acute leukemia can be either myeloid or lymphoid! Polycythemia Vera Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by panmyelosis, with an erythroid predominance. In real words: the marrow is stuffed with myeloid cells, and most of them are red cell precursors. The blood shows a markedly increased red cell count. Polycythemia" just means an increase in red blood cell mass. It may be: Primary (polycythemia vera or true polycythemia): increase in red blood cells caused by an intrinsic abnormality of myeloid cells (no in erythropoietin). Secondary: increase in red blood cells caused by secretion of erythropoietin, which may be appropriate (e.g., high-altitude living) or inappropriate (e.g., a paraneoplastic syndrome related to a solid tumor). To distinguish between primary and secondary polycythemia, and to differentiate PV from other chronic myeloproliferative disorders, a polycythemia vera study group came up with the following Polycythemia Vera Study Group Criteria (how creative). To diagnose PV, you need either (1) A1, A2, and A3, or (2) A1, A2, and any two from B: A (major) criteria A1 Increased RBC mass A2 Normal O 2 saturation in blood A3 Splenomegaly B (minor) criteria B1 Thrombocytosis B2 High WBC without infection B3 Increased leukocyte alkaline phosphatase (see box at right) without infection B4 Increased serum B 12 level Polycythemia vera: tons of red cells Things to make you look smart Q. What is leukocyte alkaline phosphatase (LAP)? A. LAP is an enzyme present in normal neutrophils. It is strangely absent in the neutrophils in CML so it was used in the olden days (before cytogenetics) to distinguish between a benign neutrophilia and CML. LAP is expressed at normal levels in the neutrophils in PV. Why is that? Who knows! But it s important because if you have a lot of neutrophils around, and you think it s a chronic myeloproliferative disorder, you could do an LAP. If it was low or zero, that would be a pretty good indicator of CML. If it was increased, it could be PV (you d still have to rule out infection though). Nowadays, we use other means to diagnose these disorders. But you ll still hear people (and books) talk about the LAP. So now you know. page 9

10 Clinical Features Polycythemia vera, like the other chronic leukemias, is a disease of older adults; the mean age at diagnosis is 60. Symptoms and signs are related to the massive increase in red cell mass. Patients may have headaches, weakness, pruritis and dizziness (from increased blood volume); they may also have symptoms of vascular stasis, thrombosis or infarction (from increased blood viscosity). Physical examination may show hepatosplenomegaly, and something called plethora, which means ruddiness or redness of the head and neck. Morphology Blood For most of the course of the disease, the red cell count is markedly increased. So are the white cell count and the platelet count. Towards the end stages of the disease, though, the marrow can become pooped out (the official name for this is spent phase ) and quit making red cells. Then the patient s red cell count goes down, and the patient may even become anemic. Bone marrow The marrow is hypercellular, with a pan-myeloid hyperplasia. Red cells make up the bulk of the myeloid cells in the marrow. Towards the end of the disease, however, the marrow may become fibrotic, and red cell production may decrease. Pathophysiology Recently, a unique genetic abnormality was found to be present in virtually all patients with polycythemia vera. There is a normal signaling pathway present in all kinds of organisms, from slime molds to humans, called the JAK-STAT (Janus kinase-signal transducer and activator of transcription) pathway. It s a pretty cool pathway because it transmits signals from outside of the cells (like growth hormone signals) to the nucleus of the cell without the need for second messengers (which most other receptors need to use). It turns out that myeloid growth and development is mediated, in part, by this pathway. Patients with polycythemia vera have a mutation in the JAK part of this pathway (specifically, in the JAK-2 gene), which makes the JAK think it s getting signals when it s not. So cells with this mutation are constantly getting signals to grow! The mutation has been found in virtually all cases of polycythemia vera (making it a great tool for differentiating primary from secondary polycythemia), and in a significant number of patients with chronic myelofibrosis and essential thrombocythemia too. Virtually all cases of polycythemia vera have a JAK-2 mutation Treatment and Prognosis Treatment usually involves phlebotomy, with or without myelosuppressive drugs. Survival is long (average 9-14 years). Dangers include thrombosis, hemorrhage, and transformation into acute leukemia. page 10

11 Essential Thrombocythemia Essential thrombocythemia (ET) is a chronic myeloproliferative disorder characterized by panmyelosis, with a megakaryocytic predominance. Meaning: the marrow is stuffed full of myeloid cells, and the predominating cell is the megakaryocyte. The blood shows a markedly increased platelet count. The diagnosis of ET is basically one of exclusion. You have to rule out benign causes of thrombocytosis and all of the other chronic myeloproliferative disorders. Here are the criteria: Platelet count must be >600 x 10 9 /L (normal = ). Hgb must be <13 g/dl or RBC mass must be normal (excludes PV). Philadelphia chromosome must be absent (excludes CML). Marrow must lack fibrosis (excludes chronic myelofibrosis). All other causes of thrombocytosis (e.g., iron deficiency anemia, cancer) must be excluded. Clinical Features ET usually occurs in patients over 50, but occasionally it occurs in young women. Symptoms are those related to thrombotic phenomena (like myocardial infarction, stroke, and deep venous thrombosis). Some patients also have excessive bleeding, which you wouldn t expect, if you have all those platelets around. The cause is a secondary (or acquired) von Willebrand disease! Weird. Physical examination may reveal mild splenomegaly, pallor and tachycardia (if the patient is anemic), and purpura and ecchymoses (if the patient has developed a secondary von Willebrand disease). tons of platelets ET: blood Morphology Blood The blood shows a ton of platelets - usually the count is over a million. The platelets usually look abnormal; they are often large and/or hypogranular. Bone marrow The bone marrow shows normal to increased cellularity, and tons of megakaryocytes, which are often described as being back-to-back. Treatment and Prognosis The main aim of treatment is to reduce the chances of hemorrhage or thrombosis. Usually platelet pheresis or myelosuppressive drugs are used to lower the platelet count. Aspirin is also used to decrease the risk of clotting. Most patients survive at least 5-8 years. Death is usually related to hemorrhage or thrombosis, but a small number of cases undergo leukemic transformation. ET: bone marrow page 11

Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms

Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)

More information

Polycthemia Vera (Rubra)

Polycthemia Vera (Rubra) Polycthemia Vera (Rubra) Polycthemia Vera (Rubra) Increased red cells Clonal Myeloid lineages also increased 2-13 cases per million Mean age: 60 years Sites of Involvement Bone marrow Peripheral blood

More information

Pathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16

Pathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16 35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will

More information

Chronic Idiopathic Myelofibrosis (CIMF)

Chronic Idiopathic Myelofibrosis (CIMF) Chronic Idiopathic Myelofibrosis (CIMF) CIMF Synonyms Agnogenic myeloid metaplasia Myelosclerosis with myeloid metaplasia Chronic granulocytic-megakaryocytic myelosis CIMF Megakaryocytic proliferation

More information

Myeloproliferative Disorders - D Savage - 9 Jan 2002

Myeloproliferative Disorders - D Savage - 9 Jan 2002 Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2

More information

Myeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:

Myeloid neoplasms. Early arrest in the blast cell or immature cell we call it acute leukemia Myoid neoplasm divided in to 3 major categories: Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid

More information

Heme 9 Myeloid neoplasms

Heme 9 Myeloid neoplasms Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia

More information

Disclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms

Disclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory

More information

Myelodysplastic Syndromes Myeloproliferative Disorders

Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes characterized by maturation defects that are associated with ineffective hematopoiesis and a high risk of transformation

More information

WBCs Disorders 1. Dr. Nabila Hamdi MD, PhD

WBCs Disorders 1. Dr. Nabila Hamdi MD, PhD WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features

More information

74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow

74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow 74y old Female with chronic elevation of Platelet count August 18, 2005 Faizi Ali, MD Hematopathology Fellow Clinical History Patient is a 74y old otherwise healthy Caucasian female with no major complaint

More information

HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Part 4 MYELOID NEOPLASMS

HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Part 4 MYELOID NEOPLASMS HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD Part 4 MYELOID NEOPLASMS Introduction: o Myeloid neoplasms are divided into three major categories: o Acute

More information

Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP

Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS

More information

MYELOPROLIFARATIVE NEOPLASMS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin).

MYELOPROLIFARATIVE NEOPLASMS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin). MYELOPROLIFARATIVE NEOPLASMS Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin). These are a group of chronic conditions characterised by clonal proliferation of marrow precursor cells. PRV, essential thrombocyathaemia,

More information

Disorders of Blood Cells & Blood Coagulation

Disorders of Blood Cells & Blood Coagulation Disorders of Blood Cells & Blood Coagulation HIHIM 409 WBC count RBC count WBC differential Hemoglobin (HGB) Hematocrit (HCT) % of volume occupied by RBCs CBC Red cell indices Mean cell volume (MCV) average

More information

Pathology of Hematopoietic and Lymphoid tissue

Pathology of Hematopoietic and Lymphoid tissue CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis

More information

Hematopathology Lab. Third year medical students

Hematopathology Lab. Third year medical students Hematopathology Lab Third year medical students Objectives Identify the lesion Know the specific name of the lesion Know associated disease Know relevant pathologic background Spherocytes: appear small,

More information

Pathology of Hematopoietic and Lymphoid tissue

Pathology of Hematopoietic and Lymphoid tissue Pathology of Hematopoietic and Lymphoid tissue Peerayut Sitthichaiyakul, M.D. Department of Pathology and Forensic Medicine Faculty of Medicine, Naresuan University CONTENTS White blood cells and lymph

More information

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour 7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic

More information

CHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009

CHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009 LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of

More information

MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA. April 16, 2008

MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA. April 16, 2008 MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA April 16, 2008 FACULTY COPY GOAL: Learn the appearance of normal peripheral blood elements and lymph nodes. Recognize abnormal peripheral blood

More information

Hematology Unit Lab 2 Review Material

Hematology Unit Lab 2 Review Material Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided

More information

The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:

The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam: Hematology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified hematologist

More information

Polycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi

Polycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi Polycythemia Vera and other Myeloproliferative Neoplasms A.Mousavi Chronic MPNs Multipotent hematopoietic progenitor cell is origin. Overproduction of one or more formed element of blood cells without

More information

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,

More information

MYELODYSPLASTIC SYNDROMES

MYELODYSPLASTIC SYNDROMES MYELODYSPLASTIC SYNDROMES Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra university hospital, Isfahan university of medical sciences Key Features ESSENTIALS OF DIAGNOSIS Cytopenias

More information

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for

More information

MYELOPROLIFERATIVE DISEASE. Dr Mere Kende MBBS (UPNG), MMED (Path),MAACB, MACTM, MACRRM (Aus) Lecturer-SMHS UPNG

MYELOPROLIFERATIVE DISEASE. Dr Mere Kende MBBS (UPNG), MMED (Path),MAACB, MACTM, MACRRM (Aus) Lecturer-SMHS UPNG MYELOPROLIFERATIVE DISEASE Dr Mere Kende MBBS (UPNG), MMED (Path),MAACB, MACTM, MACRRM (Aus) Lecturer-SMHS UPNG Myeloproliferative Diseases Essential to diagnosis Acquired clonal abnormalities of the hematopoietic

More information

رناد زكريا Dr. ahmad Dr. ahmad. P a g e 1

رناد زكريا Dr. ahmad Dr. ahmad. P a g e 1 5 رناد زكريا Dr. ahmad Dr. ahmad P a g e 1 Before we start. -This sheet was written according to section 2 s record and reviewed according to section 1 s record by Ruba Hussien with all thanks and I referred

More information

WHO Update to Myeloproliferative Neoplasms

WHO Update to Myeloproliferative Neoplasms WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories

More information

Juvenile Myelomonocytic Leukemia (JMML)

Juvenile Myelomonocytic Leukemia (JMML) Juvenile Myelomonocytic Leukemia (JMML) JMML: Definition Monoclonal hematopoietic disorder of childhood characterized by proliferation of the granulocytic and monocytic lineages Erythroid and megakaryocytic

More information

Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and

Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and / or peripheral blood Classified based on cell type

More information

Chronic Myeloproliferative Disorders

Chronic Myeloproliferative Disorders 1 Chronic Myeloproliferative Disorders 15th 9 April2015 Polycythemia vera Essential thrombocythemia Idiopathic primary myelofibrosis 2 Learning objectives To appreciate types of polycythaemia (erythrocytosis)

More information

Case Presentation No. 075

Case Presentation No. 075 Case Presentation No. 075 Session 4. Myelodysplastic Syndrome Cristina Montalvo, MD Baylor College of Medicine Houston, Texas 2007 Workshop of Society for Hematopathology and European Association for Haematopathology

More information

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic

More information

Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED

Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Acute Myeloid Leukemia Firstly we ll start with this introduction then enter the title of the lecture, so be ready and let s begin by the name of Allah : We

More information

Classification of Hematologic Malignancies. Patricia Aoun MD MPH

Classification of Hematologic Malignancies. Patricia Aoun MD MPH Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences

More information

Hematopathology Case Study

Hematopathology Case Study Hematopathology Case Study AMP Outreach Course 2009 AMP Annual Meeting John Greg Howe Ph.D. Department of Laboratory Medicine Yale University School of Medicine November 19, 2009 HISTORY Case History An

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم WBCs disorders *Slide 2: - we will focus on the disorders that are related to the # of WBCs - in children the # of lymphocyte is more than it in adults,sometimes more than neutrophils

More information

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements

More information

The Power of Peripheral Blood Smears: Apparent Diagnostic Clues (Part 1) (Wednesday, October 19, 2011)

The Power of Peripheral Blood Smears: Apparent Diagnostic Clues (Part 1) (Wednesday, October 19, 2011) The Power of Peripheral Blood Smears: Apparent Diagnostic Clues (Part 1) (Wednesday, October 19, 2011) By Gene Gulati, Ph.D., SH(ASCP) Conflict of Interest None Plan for the Course Review blood smears,

More information

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2

More information

Extramedullary precursor T-lymphoblastic transformation of CML at presentation

Extramedullary precursor T-lymphoblastic transformation of CML at presentation Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency

More information

Recommended Timing for Transplant Consultation

Recommended Timing for Transplant Consultation REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org

More information

CHALLENGING CASES PRESENTATION

CHALLENGING CASES PRESENTATION CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36

More information

Leukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College

Leukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College Leukemias Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College Introduction Leukaemias are malignant disorders of the haematopoietic stem cell compartment,

More information

WBCs Disorders. Dr. Nabila Hamdi MD, PhD

WBCs Disorders. Dr. Nabila Hamdi MD, PhD WBCs Disorders Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features and

More information

Hematology Page 1 of 8

Hematology Page 1 of 8 Hematology Page 1 of 8 Hematology Major Category Code Headings Revised 12/17 1 Basic methodology and test armamentarium 20000 2 Normal hematopoiesis & hemostasis 20100 3 RBC disorders, non-neoplastic 20340

More information

HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor

HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor I. Description of the rotation: During this rotation, the resident will gain

More information

Table 8.1. Epidemiology of Leukemia in the United States (2010) Annual Deaths. Mean Age. Percentage of All Leukemias (%) (Number of New Cases)

Table 8.1. Epidemiology of Leukemia in the United States (2010) Annual Deaths. Mean Age. Percentage of All Leukemias (%) (Number of New Cases) Table 8.1. Epidemiology of Leukemia in the United States (2010) Type of Leukemia Annual Incidence (Number of New Cases) Percentage of All Leukemias (%) Annual Deaths Mean Age Acute lymphocytic 5,330 12

More information

MPDs. Myeloproliferative Disorders OBJECTIVES MYELOPROLIFERATIVE NEOPLASMS

MPDs. Myeloproliferative Disorders OBJECTIVES MYELOPROLIFERATIVE NEOPLASMS MYELOPROLIFERATIVE NEOPLASMS CLPC Fall Seminar 2016 Angela Foley, MS, MLS(ASCP)SH LSUHSC School of Allied Health Department of Clinical Laboratory Sciences OBJECTIVES Name the 4 most common MPNs Describe

More information

HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint

HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Hematology MOC exam blueprint Based on feedback from physicians that MOC assessments should

More information

HEMATOLOGIC MALIGNANCIES BIOLOGY

HEMATOLOGIC MALIGNANCIES BIOLOGY HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION

More information

MPDs. Myeloproliferative Disorders OBJECTIVES MYELOPROLIFERATIVE NEOPLASMS

MPDs. Myeloproliferative Disorders OBJECTIVES MYELOPROLIFERATIVE NEOPLASMS MYELOPROLIFERATIVE NEOPLASMS CLPC Fall Seminar 2016 Angela Foley, MS, MLS(ASCP)SH LSUHSC School of Allied Health Department of Clinical Laboratory Sciences OBJECTIVES Name the 4 most common MPNs Describe

More information

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral

More information

HEMATOLOGIC MORPHOLOGY- AECOM HEMATOLOGY COURSE

HEMATOLOGIC MORPHOLOGY- AECOM HEMATOLOGY COURSE Log Out Help current login :lcytryn@montefiore.org HEMATOLOGIC MORPHOLOGY- AECOM HEMATOLOGY COURSE Lawrence Cytryn, M.D. - Course Director 1998 Edward Burns, M.D. Images used by permission within AECOM

More information

Disclosures/COI. Cases in Hematopathology. Outline. Heme Path Findings Not to Miss. Normal Peripheral Smear 6/30/2016

Disclosures/COI. Cases in Hematopathology. Outline. Heme Path Findings Not to Miss. Normal Peripheral Smear 6/30/2016 Disclosures/COI Cases in Hematopathology Vamsi Kota Assistant Professor Department of Hematology & Medical Oncology Leukemia/BMT I have no disclosures or conflicts of interest regarding this presentation.

More information

The Internists Approach to Polycythemia and Implications of Uncontrolled Disease

The Internists Approach to Polycythemia and Implications of Uncontrolled Disease The Internists Approach to Polycythemia and Implications of Uncontrolled Disease Mary Jo K. Voelpel, DO, FACOI, MA, CS Associate Clinical Professor MSU-COM Disclosures NONE Overview 1. Objectives 2. Case

More information

Bone marrow aspiration as the initial diagnostic tool in the diagnosis of leukemia - A case study

Bone marrow aspiration as the initial diagnostic tool in the diagnosis of leukemia - A case study Original Research Article Bone marrow aspiration as the initial diagnostic tool in the diagnosis of leukemia - A case study Priyanka Poonam 1*, N.K. Bariar 2 1 Tutor, Department of Pathology, Patna Medical

More information

Glossary of Blood, MPN, and Mutation Terms

Glossary of Blood, MPN, and Mutation Terms Glossary of Blood, MPN, and Mutation Terms Acute Lymphocytic Leukemia ALL Excess of lymphoblasts. Most common type of cancer in children with cure rate up to 80%. Cure rate for adults is up to 60%. Acute

More information

Hematopathology Case Study

Hematopathology Case Study www.medfusionservices.com Hematopathology Case Study CV3515-14 JUNE Clinical Presentation: Clinical Information: A 42 year old male with history of chronic myelogenous leukemia (CML) presents with an elevated

More information

Neoplastic proliferation arising from white blood cells. Introductory remarks. Classification

Neoplastic proliferation arising from white blood cells. Introductory remarks. Classification Neoplastic proliferation arising from white blood cells Lymphoproliferative and myeloproliferative diseases and syndromes Oliver Rácz, 2012-2017 1 Introductory remarks Leukemia and lymphoma are old descriptive

More information

BLASTIC CRISIS AND MYELOFIBROSIS SIMULTANEOUS COMPLICATIONS IN A CASE OF CHRONIC MYELOCYTIC LEUKEMIA

BLASTIC CRISIS AND MYELOFIBROSIS SIMULTANEOUS COMPLICATIONS IN A CASE OF CHRONIC MYELOCYTIC LEUKEMIA BLASTIC CRISIS AND MYELOFIBROSIS SIMULTANEOUS COMPLICATIONS IN A CASE OF CHRONIC MYELOCYTIC LEUKEMIA Abstract Pages with reference to book, From 151 To 153 Khalid Hassan ( Department of Pathology (Haematology)

More information

Diseases Of The Blood

Diseases Of The Blood Diseases Of The Blood DR. Associate Professor Of Pathology Faculty Of Medicine Ain Shams University Red Blood Cells and Anemia RBC=4-6 million/mm 2 Hb=12-18 g/dl Oxygen Carrying Molecule Hemoglobin Tetramer:

More information

CLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98

CLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98 PAGE: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes

2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes Acute basophilic leukemia 9870/3 Acute biphenotypic leukemia [OBS] 9805/3 Acute erythroid leukemia 9840/3 Acute megakaryoblastic leukemia 9910/3 Acute monoblastic and monocytic leukemia 9891/3 Acute myeloid

More information

2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes

2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes Malignant lymphoma, NOS 9590/3 Non-Hodgkin lymphoma, NOS 9591/3 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma 9596/3 Primary

More information

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma

More information

MYELOPROLIFERATIVE NEOPLASMS

MYELOPROLIFERATIVE NEOPLASMS 9 : 2 MYELOPROLIFERATIVE NEOPLASMS Introduction William Dameshek in 1951 introduced the term Myeloproliferative disorders (MPD). This included polycythemia vera (PV), essential thrombocythemia (ET), primary

More information

155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary

155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary ICD-9 TO ICD-10 Reference ICD-9 150.9 Malignant neoplasm of esophagus unspecified site C15.9 Malignant neoplasm of esophagus, unspecified 151.9 Malignant neoplasm of stomach unspecified site C16.9 Malignant

More information

YEREVAN STATE MEDICAL UNIVERSITY DEPARTMENT OF HEMATOLOGY COURSE DESCRIPTION HEMATOLOGY

YEREVAN STATE MEDICAL UNIVERSITY DEPARTMENT OF HEMATOLOGY COURSE DESCRIPTION HEMATOLOGY 1. Module/unit Code II. 1.2. 2. Module/unit Title Hematology 3. Subject Field Internal Diseases Group 4. Faculty/Department General Medicine, Department of Hematology 5. Programme(s) to which the Doctor

More information

Platelet and WBC disorders

Platelet and WBC disorders Division of Family Practice Platelet and WBC disorders Adrian Yee MD FRCPC Clinical hematologist Assistant Dean, undergraduate education, IMP asyee@uvic.ca When we understand that slide, we'll have won

More information

Transplants for MPD and MDS

Transplants for MPD and MDS Transplants for MPD and MDS The question is really who to transplant, with what and when. Focus on myelofibrosis Jeff Szer Royal Melbourne Hospital Myelodysplasia Little needs to be said Despite new therapies

More information

Peripheral Blood Smear: Diagnostic Clues and Algorithms

Peripheral Blood Smear: Diagnostic Clues and Algorithms Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Myeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination

Myeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination Myeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination Arati V. Rao, M.D. Division of Medical Oncology and Geriatrics Duke University Medical Center Durham

More information

MPL W515L K mutation

MPL W515L K mutation MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created

More information

Case Workshop of Society for Hematopathology and European Association for Haematopathology

Case Workshop of Society for Hematopathology and European Association for Haematopathology Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history

More information

Saudi Fellowship Training Program. Final Written Examination of Adult Hematology 2018

Saudi Fellowship Training Program. Final Written Examination of Adult Hematology 2018 Saudi Fellowship Training Program Final Written Examination of Adult Hematology 2018 Objectives: Determine the quantity and quality of a hematologist s knowledge base ranked as competent, so that the individual

More information

[COMPREHENSIVE GENETIC ASSAY PANEL ON

[COMPREHENSIVE GENETIC ASSAY PANEL ON 2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for

More information

Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM

Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew

More information

SAUDI FELLOWSHIP TRAINING PROGRAM. Adult Haematology. Final Written Examination 2019

SAUDI FELLOWSHIP TRAINING PROGRAM. Adult Haematology. Final Written Examination 2019 SAUDI FELLOWSHIP TRAINING PROGRAM Adult Haematology Final Written Examination 2019 Examination Format: A. The Saudi fellowship specialty final written examination shall consist of one paper with 80-120

More information

Contents SECTION 1: PHYSIOLOGY OF BLOOD

Contents SECTION 1: PHYSIOLOGY OF BLOOD Contents SECTION 1: PHYSIOLOGY OF BLOOD Chapter 1: Overview of Physiology of Blood 1 Normal Haematopoiesis 1 Red Blood Cells 6 White Blood Cells 15 Immune System 27 Megakaryopoiesis 32 Normal Haemostasis

More information

WHO Classification 7/2/2009

WHO Classification 7/2/2009 Least Malignant Myeloproliferative Disorders Myelodysplastic Syndromes Most Malignant Acute Leukemia Classifying Hematopoietic Disorders French-American-British (FAB) World Health Organization (WHO) Thanks

More information

Emergency Medical Training Services Emergency Medical Technician Paramedic Program Outlines Outline Topic: HEMATOLOGY Revised: 11/2013

Emergency Medical Training Services Emergency Medical Technician Paramedic Program Outlines Outline Topic: HEMATOLOGY Revised: 11/2013 Emergency Medical Training Services Emergency Medical Technician Paramedic Program Outlines Outline Topic: HEMATOLOGY Revised: 11/2013 What type of tissue is blood? Blood is considered liquid connective

More information

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish

More information

July 3, The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244

July 3, The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 July 3, 2013 The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: Physician Compare Intelligent Search To Whom it May Concern, The American

More information

MDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?

MDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do? 101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone

More information

John L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine St Louis, Missouri

John L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine St Louis, Missouri Myeloproliferative Neoplasms: New Approaches to Diagnosis and Disease Monitoring John L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine

More information

Polycythemia Vera and Essential Thombocythemia A Single Institution Experience

Polycythemia Vera and Essential Thombocythemia A Single Institution Experience INDIAN JOURNAL OF MEDICAL & PAEDIATRIC ONCOLOGY Vol. 29 No 4, 2008 7 Original Article-I Polycythemia Vera and Essential Thombocythemia A Single Institution Experience CECIL ROSS, NAVYA, VANAMALA AND KARUNA

More information

Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms

Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms Sonam Prakash declares affiliation with Incyte Corporation: Advisor for Hematopathology Publications Steering Committee Sonam Prakash,

More information

Normal Development. Normal Development 10/16/2012. Hematopoietic and Lymph Node Pathology. Red Blood Cell Maturation & Anemias

Normal Development. Normal Development 10/16/2012. Hematopoietic and Lymph Node Pathology. Red Blood Cell Maturation & Anemias Hematopoietic and Lymph Node Pathology Normal Development Red Blood Cell Maturation & Anemias Normal Development Differentiation of Hematopoietic Cells 1 Bone Marrow Bone Marrow Bone Marrow, RBC Precursors

More information

3/5/2013. Hematopoiesis: Red and white marrow. Hematopoiesis. Bone marrow aspirate and core biopsy. Gartner, Color Textbook of Histology, 3 rd Edition

3/5/2013. Hematopoiesis: Red and white marrow. Hematopoiesis. Bone marrow aspirate and core biopsy. Gartner, Color Textbook of Histology, 3 rd Edition Hematopoiesis Hematopoiesis: Red and white marrow Bone marrow aspirate and core biopsy Gartner, Color Textbook of Histology, 3 rd Edition 1 reticulocytes elliptocytes schistocytes spheroctyes target cells

More information

Leukemia and Myelodysplastic Syndromes

Leukemia and Myelodysplastic Syndromes Leukemia and Myelodysplastic Syndromes Lenise Taylor, RN, MN, AOCNS Heme Malignancies/BMT CNS Seattle Cancer Care Alliance/UWMC Lymphoid 1 Myeloid 2 Presenting Signs and Symptoms Diagnostic Evaluation

More information

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic

More information

Bone marrow histopathology in Ph - CMPDs. - the new WHO classification - Juergen Thiele Cologne, Germany

Bone marrow histopathology in Ph - CMPDs. - the new WHO classification - Juergen Thiele Cologne, Germany Bone marrow histopathology in Ph - CMPDs - the new WHO classification - Juergen Thiele Cologne, Germany Current issues in MPNs concerning morphology 1.Prodromal stages of disease 2.Impact of histopathology

More information

POLYCYTHEMIA VERA (PV)

POLYCYTHEMIA VERA (PV) LIVING WITH POLYCYTHEMIA VERA (PV) Information, resources, and support for wherever you are on your journey with PV. For more information, visit PVvoices.com today. POLYCYTHEMIA VERA (polly-sigh-thee-me-ah-vair-ah)

More information

2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228

2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 Vishnu V. B Reddy, MD University of Alabama at Birmingham Birmingham, AL USA 11/03/07

More information